Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report released on Tuesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Separately, BTIG Research raised shares of Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Stock Up 0.8 %

Shares of Accelerate Diagnostics stock opened at $1.32 on Tuesday. Accelerate Diagnostics has a 12-month low of $0.73 and a 12-month high of $2.09. The firm has a market capitalization of $33.05 million, a PE ratio of -0.46 and a beta of 0.59. The stock’s fifty day moving average is $1.29 and its 200-day moving average is $1.54.

Insider Buying and Selling at Accelerate Diagnostics

In other Accelerate Diagnostics news, Director John Patience bought 200,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were bought at an average price of $1.57 per share, for a total transaction of $314,000.00. Following the acquisition, the director now directly owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 43.60% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned approximately 0.08% of Accelerate Diagnostics as of its most recent SEC filing. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.